Allergan CEO settles into leading new company; Botox for depression?
Jeffrey Clark - Posted: 6/24/2015
Allergan President and CEO Brent Saunders is now settling into his new role leading the combined Actavis/Allergan organization after one of the most successful deals of the past 12 months. Most revealing from his interview might be the early stage te[...]
United Therapeutics CEO does it her own way
Jeffrey Clark - Posted: 6/23/2015
United Therapeutics CEO Martine Rothblatt talks with CNBC about the future of transplants and near-term RNA techniques. Rothblatt is easily one of the most fascinating CEOs in the life sciences, having previously founded Sirius Radio before launching[...]
Drug industry pushes for 12-year exclusivity period in trade deal
Jeffrey Clark - Posted: 6/19/2015
The Trans-Pacific Partnership (TPP) is poised to be the largest free-trade deal in history. Part of the TPP negotiations have the biopharmaceutical industry pushing for a 12-year exclusivity period.  Among the 12 parties to TPP, the United States is [...]
Regeneron CEO talks new cholesterol drugs
Jeffrey Clark - Posted: 6/17/2015
Regeneron CEO Leonard Schleifer talks about an FDA panels approval of Sanofi-Regenerons new cholesterol-lowering drugs. An FDA advisory committee on Tuesday recommended approval of a new type of experimental cholesterol-fighting drug that could be mo[...]
Exact Sciences CEO talks cancer screening diagnostics
Jeffrey Clark - Posted: 6/16/2015
When Kevin Conroy took over as CEO of Exact Sciences in 2009, the molecular-diagnostics company was facing delisting from the NASDAQ with its stock trading for $1. Today, he is on CNBC discussing the development of an early stage, blood-based diagnos[...]
Endochoice CEO on NYSE following IPO
Jeffrey Clark - Posted: 6/15/2015
EndoChoice President and CEO Mark Gilreath discusses the companys recent initial public offering, growth and new technology. The Atlanta-based companys product is full spectrum endoscopy that provides a better solution for colonoscopies.
Statins beware: Next generation of cholesterol drugs about to arrive
Jeffrey Clark - Posted: 6/11/2015
With ASCO in our rear view mirror, the talk in Big Pharma has shifted from immune-oncology to cholesterol, as a new generation of drugs prepares to be reviewed by FDA advisory panels this week.
BMS and Astrazeneca feud over research executive, lawsuit pending
Jeffrey Clark - Posted: 6/10/2015
There is a battle being waged amongst the biggest drug makers in the world. It is a race to market with the latest generation of cancer treatments powered by the body’s own immune system. Immuno-oncology is on fire and looks to be the growth engine f[...]
Edwards CEO talks heart surgery on CNBC
Jeffrey Clark - Posted: 6/9/2015
Edwards Lifesciences CEO Mike Mussallem discusses major strides the medical community has made in cardiovascular treatment.
Clovis Oncology stars at ASCO
Jeffrey Clark - Posted: 6/8/2015
Last week, analysts predicted that Clovis Oncology would be closely watched at ASCO. Clovis is in a race with AstraZeneca to bring a new lung cancer drug to market. Clovis Oncology CEO Patrick Mahaffy was interviewed by CNBC in Chicago:
Highlights from ASCO in Chicago
Jeffrey Clark - Posted: 6/4/2015
The American Society of Clinical Oncology (ASCO) wrapped up their annual meeting in Chicago this weekend. Where last year immunotherapy was heating up as the most promising future for oncology therapy, this year it was on fire. Merck dominated in col[...]
Pfizer CEO talks oncology drugs at ASCO
Jeffrey Clark - Posted: 6/3/2015
Pfizer Chairman and CEO Ian Read spoke with CNBC at ASCO in Chicago this weekend.
Sprout pushes female Viagra back to FDA
Jeffrey Clark - Posted: 6/3/2015
Sprout Pharmaceuticals is a little-known drug company headquartered in Raleigh, North Carolina. Sprout holds the right to a not-so-new new drug called flibanserin could help women regain their sexual desire. Twice the drug has been rejected by FDA. B[...]
Merck research chief Perlmutter talks immunotherapy in oncology
Jeffrey Clark - Posted: 6/2/2015
Roger Perlmutter is a legend in drug research and development. His recruitment from Merck to Amgen in 2001 was one of the highest profile executive moves in the history of our industry. Now back at Merck, Dr. Perlmutter discusses research on immunoth[...]
Medical device tax repeal effort continues
Jeffrey Clark - Posted: 5/29/2015
A budget proposal that includes language to repeal the 2.3% excise tax on medical devices was introduced by Republicans in the U.S. Senate. The medical device tax has harmed health care innovation, stifled job creation and burdened the delivery of qu[...]
WSJ: European life sciences companies move toward US markets, higher valuations
Jeffrey Clark - Posted: 5/29/2015
Life sciences stocks have been on a tear.  The NASDAQ Biotechnology Index (NBI) is up more than 50% from last year and has outpaced the S&P 500 by roughly 250% since 2009. And with US markets and their demand for life sciences stocks at an all time h[...]
Dueling super conferences: ASM in New Orleans, ASCO in Chicago
Jeffrey Clark - Posted: 5/28/2015
The majority of drug companies, especially in oncology, have their sights trained on Chicago where ASCOs 2015 Annual Meeting kicks off tomorrow. But if all the drug companies are headed to the Midwest, the diagnostics world is going down south where [...]
Spark Therapeutics: Where once I was blind, now I can see
Jeffrey Clark - Posted: 5/28/2015
Spark Therapeutics CEO Jeffrey Marrazzo discuss how advances in gene therapy are changing the way rare diseases are treated. Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing one-time, life-alter[...]
In oncology? Better be at ASCO on Friday
Jeffrey Clark - Posted: 5/26/2015
ASCO starts later this week in Chicago, as one of the most critical and influential conferences for the life sciences meeting. ASCO 2015 is sponsored by every leading oncology drug company and brings together 30,000 oncology professionals from around[...]
Johnson and Johnson CEO on his strategy for acquisitions
Jeffrey Clark - Posted: 5/25/2015
Johnson & Johnson Chairman & CEO Alex Gorsky discusses the companys search for new scientific platforms and potential M&A prospects.
Johnson and Johnson CEO talks diversification and taxes
Jeffrey Clark - Posted: 5/21/2015
Johnson and Johnson CEO Alex Gorsky shares his point of view on the diversified strategy for the company, touching on the value of crossing over between medical devices, pharmaceuticals and consumer products. He also touches on the global economic im[...]
Johnson and Johnson CEO Alex Gorsky highlights innovation
Jeffrey Clark - Posted: 5/21/2015
In a series of interview clips on CNBC, Johnson & Johnson Chairman & CEO Alex Gorsky discusses new drugs in the companys development pipeline, with the biggest potential in oncology.
Vertex takes big step toward fulfilling lofty expectations
Jeffrey Clark - Posted: 5/19/2015
Vertex Pharmaceuticals experimental cystic fibrosis treatment Orkambi won the backing of a Food and Drug Administration advisory committee on Tuesday, which voted 12 to 1 to recommend approval of the drug.  The vote was important for Vertex, a compan[...]
Halozyme CEO talks products, drug delivers on CNBC
Jeffrey Clark - Posted: 5/18/2015
Halozyme CEO Helen Torley was in studio with CNBC this morning discussing a new drug that is disrupting the way cancer patients are treated.  Most relevant to Halozyme is the news about new drug delivery solutions for popular cancer treatments beyond[...]
Cool Technology: ConforMIS custom orthopedic implants
Jeffrey Clark - Posted: 5/14/2015
ConforMIS does something that no other knee replacement company does – design and manufacture customized knee implants for each patient. According to their product profile, no two are alike.   The company uses MRI imaging and 3D print[...]
Allergan CEO settles into[...]
Allergan President and CEO Brent Saunders is now settling into his new role leading the combined Act[...]
United Therapeutics CEO d[...]
United Therapeutics CEO Martine Rothblatt talks with CNBC about the future of transplants and near-t[...]
Regeneron CEO talks new c[...]
Regeneron CEO Leonard Schleifer talks about an FDA panel’s approval of Sanofi-Regeneron’s new choles[...]
Exact Sciences CEO talks [...]
When Kevin Conroy took over as CEO of Exact Sciences in 2009, the molecular-diagnostics company was [...]
Endochoice CEO on NYSE fo[...]
EndoChoice President and CEO Mark Gilreath discusses the company’s recent initial public offering, g[...]